The Shuman Law Firm Announces The Filing Of A Securities Class Action Lawsuit Against Abiomed, Inc.

The Shuman Law Firm today announced that a lawsuit seeking class action status has been filed in the U.S. District Court for the District of Massachusetts on behalf of purchasers of Abiomed, Inc. (“Abiomed” or the “Company”) (Nasdaq: ABMD) securities between August 5, 2011 and October 31, 2012, inclusive (the “Class Period”).

If you wish to discuss this action or have any questions concerning this notice or your rights and interests with respect to this matter, please contact Kip B. Shuman or Rusty E. Glenn toll free at [phone] or email Mr. Shuman at [e-mail] or Mr. Glenn at [e-mail].

The Complaint alleges that throughout the Class Period the defendants made materially false and misleading statements regarding the Company’s business, operations and financial prospects. Specifically, defendants misrepresented and/or failed to disclose that: (1) the Company was improperly marketing and/or labeling its Impella 2.5 system; (2) Abiomed’s financial results would be materially impacted if the Company were either forced to stop or discontinued its improper conduct; (3) the Company lacked adequate internal and financial controls; and (4) as a result of the foregoing, the Company’s statements were materially false and misleading at all relevant times.

On November 1, 2012, prior to the opening of the markets, Abiomed disclosed that the United States Attorney’s Office for the District of Columbia was conducting an investigation into Abiomed’s marketing and labeling of its Impella 2.5 system. As a result of this news, shares of Abiomed declined $6.31 per share, or 31.33%, to close on November 1, 2012 at $13.61, on heavy trading volume.

If you are a member of the proposed class, you may request that the Court appoint you as lead plaintiff of the class no later January 15, 2013. A lead plaintiff is a class member that acts on behalf of other class members in directing the litigation. Although your ability to share in any recovery is not affected by the decision whether or not to seek appointment as a lead plaintiff, lead plaintiffs make important decisions which could affect the overall recovery for class members.

1 2 Next › Last »